The two branches of the autonomic nervous system (ANS) have been individually linked to age-related changes in cognitive functioning: The parasympathetic nervous system (PNS) is thought to support healthy cognitive aging, whereas the sympathetic nervous system (SNS) has been linked to heightened cognitive decline. Despite these separate findings and despite the integrative nature of the ANS, little work has examined the two branches simultaneously to better understand their interactive effects on age-related cognitive changes. We examined cognitive change in two waves of the MIDUS cognitive project and indexed PNS and SNS activity from heart rate variability and epinephrine levels (respectively) from the MIDUS biomarker project (n = 764, 56% female, mean age = 54.1 years). Our findings indicate that higher PNS levels attenuate cognitive decline, but only among individuals with low SNS levels; at higher SNS levels, the beneficial effects of the PNS are blocked. Further, lower PNS levels can be somewhat compensated for by increased SNS levels. This pattern was most robust among individuals transitioning to mid-life (i.e., 35-40 years old at the initial cognitive test). These results suggest that interventions targeting the ANS as a modifiable factor in cognitive aging should consider both ANS branch's effects simultaneously, particularly in the early stages of midlife. Therapeutic interventions for Alzheimer's disease (AD) remain limited due to an incomplete understanding of the molecular mechanisms of its onset and progression. Cerebrovascular dysfunction occurs early during disease development. Attenuation of mTOR, a key regulator of aging, attenuates and reverses cerebrovascular deficits by restoring cerebral blood flow, brain vascular density, neurovascular coupling, and vascular amyloid-β clearance in hAPP(J20) mice expressing human amyloid precursor protein carrying two FAD-associated mutations. The mechanisms by which mTOR attenuation alleviates AD pathology are poorly understood. This study defined changes in the microvascular proteome of hAPP(J20) mice arising from mTOR attenuation. At 7 months of age, hAPP(J20) mice were fed vehicle-or rapamycinsupplemented diet (2.24 mg/kg/day) for 4 months. Mass spectrometry of collected brain microvasculature identified significant changes in 840 of 3361 proteins (p<0.05). mTOR attenuation led to significant changes in 26 of these proteins, some of which are involved in pathways including tight junction regulation, calcium signaling, and actin cytoskeleton regulation. Candidate mediators of mTOR-driven cerebrovascular dysfunction were identified by selecting proteins that were aberrantly altered in hAPP(J20) microvasculature and normalized by rapamycin. Examples include members of the heterogeneous nuclear ribonucleoprotein family (hnRNPA/B, hnRNPD) which regulate the mRNA stability of genes related to cellular cycle arrest and inflammatory cytokines as well as localization of crucial mRNA involved in nitric oxide signaling. Also included are nucleoporin 54 and vacuolar ATPase assembly factor, both of which are altered in aging and neurodegeneration. Subsequent studies will elucidate the role of these proteins in mTOR-driven cerebrovascular dysfunction in AD. Medicine, Halifax, Nova Scotia, Canada, 3. Dalhousie University, Halifax, Nova Scotia, Canada Laboratory test-based frailty indices (FI) are known to be highly predictive of adverse health outcomes and mortality. However, these FI depend on the proper classification of continuous valued health measurements into binary deficits (healthy or unhealthy). This classification is not standardized and is often done by using thresholds for medical intervention or maximally predictive values from statistical tests. This work proposes a simple and generic methodology for the creation of FI from laboratory values and measures its performance against existing methods. The methodology is as follows: a direction of risk is determined for each measurement, individuals are then assigned a score based on their relative standing in the population, binarization is then done using a global cutpoint which binarizes all measures based on a given quantile. This method is shown to outperform FI created with medical risk thresholds for a range of global cut-points in both the NHANES and CSHA studies. Furthermore, our method is shown to be more robust to cohort effects than FI created using cut-points determined by maximum information measures, such as maximal separation of survival curves. Mice that overexpress mutant human tau in forebrain neurons develop many features of Alzheimer's disease (AD), including behavioral impairments and neurodegeneration by 5 months of age. While an appropriate model to study AD-like pathology, the transgene's high neurotoxicity makes it difficult to investigate how aging impacts AD onset and progression. The removal of endogenous mouse tau decreases the transgene's neurotoxicity in young mice, which has allowed us to age mice to 20 months of age and investigate behavior at a more AD-relevant stage of life. Interestingly, the tau transgenic mice show increased discrimination between familiar and unfamiliar objects than non-transgenic littermates (p = 0.02) suggesting tau transgenic mice have better memory. The transgenic mice also displayed increased physical activity in the Open Field Test than non-transgenic littermates (distance traveled, p = 0.0102, and gait speed, p = 0.0219). Their improved behavioral performance occurred despite significant forebrain atrophy (20% smaller, p=0.0003). Interestingly, the non-transgenic control mice lacking endogenous mouse tau developed insulin resistance and obesity, and had significantly smaller cerebellum than transgenic mice (10% smaller, p = 0.0007). These data suggest that insulin resistance and obesity contribute more profoundly to poor behavioral performance than forebrain neurodegeneration. Moreover our study suggests that the cerebellum, recognized primarily for its role in coordination and motor function, may be an important mediator of late life cognitive function, especially in the presence of insulin resistance and obesity. This study investigates the role of microglia activity in stress-induced depression and anxiety and the mechanisms associated with the role of certain microbiome derived anti-inflammatory polyphenols in attenuating stressinduced microglia immune priming and symptoms of depression. We implemented a chronic unpredictable stress (CUS) paradigm to exhibit priming of microglia innate immunity in the context of the onset of depression and anxiety phenotypes. Mechanistic studies related to prophylactic treatment using dietary microbiome derived polyphenols were also investigated in this model. Depression and anxiety phenotypes, gene expression in microglia and protein expression in the cortex of mice were measured following a primary exposure to short-term unpredictable stress (US) followed by CUS. We examined the long-term, persistent CUS induced changes at 4-weeks of post-stress rest following a secondary US exposure. We found depression phenotypes resulted from US only following exposure to CUS. This was accompanied by an increase and persistent upregulation of toll-like receptor 4 (TLR4), RAGE, and HMGB1 gene expression in isolated cortical microglia. Priming by CUS also amplified gene expression of IL-1β in microglia and protein IL-1β in the cerebral cortex following US re-exposure. Increased activity of NF-kB was also noted in the period following CUS. Furthermore, polyphenol treatment prevented stress-induced phenotypes, upregulation of HMGB1, IL-1B, and TLR4 gene expression, as well as upregulation of IL-1β and NF-kB. The study suggests that latent activity of the TLR4-NFkB-IL1β pathway contributes to immune priming and increases susceptibility to depression-like behaviors. Anti-depressant effects of polyphenols may result from their ability to attenuate microglia priming. The purpose of this study was to determine if inhibitors of innate immunity in microglia could attenuate sleep deprivation (SD)-induced psychological impairment, which involve the assembly and activation of the NLRP3 inflammasome. In the study, CD-1 mice were immuneprimed with chronic corticosterone treatment (20 mg/kg IP) for two weeks and were subsequently subjected to one bout of 6 hr SD. Mice were sacrificed immediately afterward to measure cytokine concentrations and caspase-1 activity. We found a significant upregulation of caspase-1 activity in the brain of both mice primed with corticosterone then subjected to sleep deprivation as well as mice only subjected to sleep deprivation (p < 0.01). Increased caspase-1 was NLRP3-dependent as treatment with MCC950 (20 mg/kg IP), an inhibitor of NLRP3 inflammasome assembly, completely attenuated SD-induced caspase-1 activity (p < 0.01). Additionally, in SD mice we observed increased microglia reactivity as quantified by IBA+ cells and an increased number of microglia that had reactive amoeboid morphologies, as measured through immunohistochemistry. The administration of the NLRP3 specific inhibitor MCC950 similarly prevented SD-induced changes in microglia morphology. The study established that consequential effects of SD-induced inflammasome activation and microglia activation could be prevented by a selective NLRP3 inhibitor. Given the preliminary beneficial effects of targeting NLRP3 in SD, future investigations will establish the clinical efficacy of microbiome-derived polyphenolic compounds, which we have shown provide protection against neuroinflammation in models of stress induced psychological impairment, to attenuate SD neuroinflammation by targeting the NLRP3 inflammasome.
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